Prosecution Insights
Last updated: April 19, 2026
Application No. 18/411,786

DEVICE FOR DELIVERY OF AEROSOLIZED DRUG IN A PORTION OF A BODY

Non-Final OA §112
Filed
Jan 12, 2024
Examiner
KIM, CHRISTOPHER S
Art Unit
3752
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Curotherm Techno Solutions LLP
OA Round
1 (Non-Final)
63%
Grant Probability
Moderate
1-2
OA Rounds
3y 4m
To Grant
84%
With Interview

Examiner Intelligence

Grants 63% of resolved cases
63%
Career Allow Rate
705 granted / 1118 resolved
-6.9% vs TC avg
Strong +21% interview lift
Without
With
+21.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
46 currently pending
Career history
1164
Total Applications
across all art units

Statute-Specific Performance

§101
0.3%
-39.7% vs TC avg
§103
22.6%
-17.4% vs TC avg
§102
33.8%
-6.2% vs TC avg
§112
38.3%
-1.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1118 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-18 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 1 recites the limitation "aerosolized drug" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation “distally” in line 3. The claim fails to define a reference to determine a distal direction. Claim 1 recites the limitation "atomization" in line 7. There is insufficient antecedent basis for this limitation in the claim. Claim 1 recites the limitation "the drug" in line 7. There is insufficient antecedent basis for this limitation in the claim. It appears to be a double inclusion of the “aerosolized drug” recited in line 1 and/or the “liquid film” recited in line 7. The term “optimized” in claim 1 is a relative term which renders the claim indefinite. The term “optimized” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The amplitude limited by the claim is uncertain. Clam 1 recites the limitation “a proximal end” in line 10. The claim fails to define a reference to determine “proximal.” Claim 1 recites the limitation "tubing" in line 10. There is insufficient antecedent basis for this limitation in the claim. Clam 1 recites the limitation “a proximal end” in line 14. The claim fails to define a reference to determine “proximal.” Clam 1 recites the limitation “a distal end” in line 15. The claim fails to define a reference to determine “proximal.” The term “maximum” in claim 2 is a relative term which renders the claim indefinite. The term “maximum” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The amplification limited by the claim is uncertain. Claim 4 recites the limitation “reduce” in line 2. The claim fails to define a reference to determine “reduce.” The term “fine” in claim 4 is a relative term which renders the claim indefinite. The term “fine” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The atomization limited by the claim is uncertain. The term “adjacent” in claim 12 is a relative term which renders the claim indefinite. The term “adjacent” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The location/distance limited by the claim is uncertain. Claim 13 is indefinite because it depends on itself. The term “adjacent” in claim 13 is a relative term which renders the claim indefinite. The term “adjacent” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. The location/distance limited by the claim is uncertain. Claim 14 recites the limitation "frequency" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 14 recites the limitation "vibration" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 14 recites the limitation “drug” in line 3. It appears to be a double inclusion of the “drug” recited in claim 1. Claim 14 recites the limitation "its liquid form" in line 3. There is insufficient antecedent basis for this limitation in the claim. Claim 15 recites the limitation "the frequency" in line 1. There is insufficient antecedent basis for this limitation in the claim. Claim 16 recites the limitation "titanium metal" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 16 recites the limitation "titanium alloy" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 17 recites the limitation “a drug” in line 2. It appears to be a double inclusion of the “drug” recited in claim 1. In claim 18, the recitation “having frequency 20 - 80 KHz” is grammatically incorrect. The claims are generally narrative and indefinite, failing to conform with current U.S. practice. They appear to be a literal translation into English from a foreign document and are replete with grammatical and idiomatic errors. The above listing is only exemplary. Applicant is required to review and amend all of the claims in their entirety to ensure full compliance with 35 U.S.C. 112(b). Applicant should not misconstrue the lack of art rejection as an indication of allowable subject matter. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHRISTOPHER S KIM whose telephone number is (571)272-4905. The examiner can normally be reached M-F 7:30-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Arthur O Hall can be reached at (571) 270-1814. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHRISTOPHER S KIM/Primary Examiner, Art Unit 3752 CHRISTOPHER S. KIM Examiner Art Unit 3752 CK
Read full office action

Prosecution Timeline

Jan 12, 2024
Application Filed
Oct 23, 2025
Non-Final Rejection — §112
Apr 02, 2026
Interview Requested
Apr 09, 2026
Applicant Interview (Telephonic)
Apr 09, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599730
SYSTEM AND METHOD FOR A FLUID DISPERSAL CARTRIDGE
2y 5m to grant Granted Apr 14, 2026
Patent 12594565
SPRAY GUN WITH ADJUSTABLE ATOMIZER AND REMOVABLE NOZZLE BODY
2y 5m to grant Granted Apr 07, 2026
Patent 12589399
WATER DISCHARGE DEVICE
2y 5m to grant Granted Mar 31, 2026
Patent 12551741
RIDGE SEAL FOR FIRE SPRINKLER
2y 5m to grant Granted Feb 17, 2026
Patent 12544785
APPARATUS FOR PRODUCING RECONFIGURABLE WALLS OF WATER
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
63%
Grant Probability
84%
With Interview (+21.2%)
3y 4m
Median Time to Grant
Low
PTA Risk
Based on 1118 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month